Creating new antibodies to fight cancer
Developing novel bispecific antibodies for cancer treatment
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10886105
This study is testing new types of antibodies that can help your body fight cancer by targeting both the cancer cells and their surroundings, with the hope of making treatments more effective and improving survival rates for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10886105 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative bispecific antibodies (BsAbs) that target cancer cells and the tumor environment to enhance cancer treatment. The approach involves designing antibodies that can bind to both a specific cancer cell marker and a growth factor present in the tumor, promoting the destruction of cancer cells more effectively than traditional therapies. By using these novel antibodies, the research aims to improve the immune response against cancer metastasis, potentially leading to better patient outcomes. Preliminary studies have shown promising results in mouse models, indicating that these antibodies could significantly prolong survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that overexpress HER2 or are affected by tumor angiogenesis.
Not a fit: Patients with cancers that do not express HER2 or are not influenced by angiogenesis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve survival rates for patients with various types of cancer.
How similar studies have performed: Other research has shown success with bispecific antibodies in cancer treatment, indicating a promising avenue for further exploration.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FAN, ZHEN — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: FAN, ZHEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.